


Atty. Docket No.: PG3119US2

In the Claims:

A complete listing of claims 1-19 with status identifier follows.

Claim 1 (Currently Amended) A method of treating a susceptible cancer in a human or animal subject in need thereof, comprising administering to said subject an effective amount of a compound of formula (I):



or a salt or solvate thereof;

wherein X is N or CH;

Y is a group W(CH<sub>2</sub>), (CH<sub>2</sub>)W, or W, in which W is O, S(O)<sub>m</sub> wherein m is 0, 1 or 2, or NR<sup>a</sup> wherein R<sup>a</sup> is hydrogen or a C<sub>1-8</sub> alkyl group;

R<sup>1</sup> ~~is represents~~ a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from the group N, O or S(O)<sub>m</sub>, wherein m is as defined above, with the provisos that the ring does not have two adjacent O or S(O)<sub>m</sub> atoms and that where the ring has only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R<sup>1</sup> being optionally substituted by one or more R<sup>3</sup> groups;

each R<sup>3</sup> is independently selected from the group consisting of amino, hydrogen, halogen, hydroxy, nitro, carboxy, formyl, cyano, trifluoromethyl,

Atty. Docket No.: PG3119US2

trifluoromethoxy, carbamoyl, ureido, guanidino, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkoxy, C<sub>3-8</sub> cycloalkoxyl, C<sub>4-8</sub> alkylcycloalkoxy, C<sub>1-8</sub> alkylcarbonyl, C<sub>1-8</sub> alkoxycarbonyl, N-C<sub>1-4</sub> alkylcarbamoyl, N,N-di-[C<sub>1-4</sub> alkyl]carbamoyl, hydroxyamino, C<sub>1-4</sub> alkoxyamino, C<sub>2-4</sub> alkanoyloxyamino, C<sub>1-4</sub> alkylamino, di[C<sub>1-4</sub> alkyl]amino, di-[C<sub>1-4</sub> alkyl]amino-C<sub>1-4</sub> alkylene-(C<sub>1-4</sub> alkyl)amino, C<sub>1-4</sub> alkylamino-C<sub>1-4</sub> alkylene-(C<sub>1-4</sub> alkyl)amino, hydroxy-C<sub>1-4</sub> alkylene-(C<sub>1-4</sub> alkyl)amino, phenyl, phenoxy, 4-pyridon-1-yl, pyrrolidin-1-yl, imidazol-1-yl, piperidino, morpholino, thiomorpholino, thiomorpholino-1-oxide, thiomorpholino-1,1-dioxide, piperazin-1-yl, 4-C<sub>1-4</sub> alkylpiperazin-1-yl, dioxolanyl, C<sub>1-8</sub> alkylthio, arylthio, C<sub>1-4</sub> alkylsulphinyl, C<sub>1-4</sub> alkylsulphonyl, arylsulphonyl, arylsulphinyl, halogeno-C<sub>1-4</sub> alkyl, hydroxy-C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkanoyloxy-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, carboxy-C<sub>1-4</sub> alkyl, formyl-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxycarbonyl-C<sub>1-4</sub> alkyl, carbamoyl-C<sub>1-4</sub> alkyl, N-C<sub>1-4</sub> alkylcarbamoyl-C<sub>1-4</sub> alkyl, N,N-di-[C<sub>1-4</sub> alkyl]carbamoyl-C<sub>1-4</sub> alkyl, amino-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylamino-C<sub>1-4</sub> alkyl, di-[C<sub>1-4</sub> alkyl]amino-C<sub>1-4</sub> alkyl, phenyl-C<sub>1-4</sub> alkyl, 4-pyridon-1-yl-C<sub>1-4</sub> alkyl, pyrrolidin-1-yl-C<sub>1-4</sub> alkyl, imidazol-1-yl-C<sub>1-4</sub> alkyl, piperidino-C<sub>1-4</sub> alkyl, morpholino-C<sub>1-4</sub> alkyl, thiomorpholino-C<sub>1-4</sub> alkyl, thiomorpholino-1-oxide-C<sub>1-4</sub> alkyl, thiomorpholino-1,1-dioxide-C<sub>1-4</sub> alkyl, piperazin-1-yl-C<sub>1-4</sub> alkyl, 4-C<sub>1-4</sub> alkylpiperazin-1-yl-C<sub>1-4</sub> alkyl, hydroxy-C<sub>2-4</sub> alkoxy-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>2-4</sub> alkoxy-C<sub>1-4</sub> alkyl, hydroxy-C<sub>2-4</sub> alkylamino-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>2-4</sub> alkylamino-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylthio-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulphinyl-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulphonyl-C<sub>1-4</sub> alkyl, hydroxy-C<sub>2-4</sub> alkylthio-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>2-4</sub> alkylthio-C<sub>1-4</sub> alkyl, phenoxy-C<sub>1-4</sub> alkyl, anilino-C<sub>1-4</sub> alkyl, phenylthio-C<sub>1-4</sub> alkyl, cyano-C<sub>1-4</sub> alkyl, halogeno-C<sub>2-4</sub> alkoxy, hydroxy-C<sub>2-4</sub> alkoxy, C<sub>2-4</sub> alkanoyloxy-C<sub>2-4</sub> alkoxy, C<sub>1-4</sub> alkoxy-C<sub>2-4</sub> alkoxy, carboxy-C<sub>1-4</sub> alkoxy, formyl-

Atty. Docket No.: PG3119US2

C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkoxycarbonyl-C<sub>1-4</sub> alkoxy, carbamoyl-C<sub>1-4</sub> alkoxy, N-C<sub>1-4</sub> alkylcarbamoyl-C<sub>1-4</sub> alkoxy, N,N-di-[C<sub>1-4</sub> alkyl]carbamoyl-C<sub>1-4</sub> alkoxy, amino-C<sub>2-4</sub> alkoxy, C<sub>1-4</sub> alkylamino-C<sub>2-4</sub> alkoxy, di-[C<sub>1-4</sub> alkyl]amino-C<sub>2-4</sub> alkoxy, di-[C<sub>1-4</sub> alkyl-C<sub>2-4</sub> alkoxy]amino-C<sub>2-4</sub> alkoxy, C<sub>2-4</sub> alkanoyloxy, hydroxy-C<sub>2-4</sub> alkanoyloxy, C<sub>1-4</sub>alkoxy-C<sub>2-4</sub> alkanoyloxy, phenyl-C<sub>1-4</sub> alkoxy, phenoxy-C<sub>2-4</sub> alkoxy, anilino-C<sub>2-4</sub> alkoxy, phenylthio-C<sub>2-4</sub> alkoxy, 4-pyridon-1-yl-C<sub>2-4</sub> alkoxy, piperidino-C<sub>2-4</sub> alkoxy, morpholino-C<sub>2-4</sub> alkoxy, thiomorpholino-C<sub>2-4</sub> alkoxy, thiomorpholino-1-oxide-C<sub>2-4</sub> alkoxy, thiomorpholino-1,1-dioxide-C<sub>2-4</sub> alkoxy, piperazin-1-yl-C<sub>2-4</sub> alkoxy, 4-C<sub>1-4</sub> alkylpiperazin-1-yl-C<sub>2-4</sub> alkoxy, pyrrolidin-1-yl-C<sub>2-4</sub> alkoxy, imidazol-1-yl-C<sub>2-4</sub> alkoxy, halogeno-C<sub>2-4</sub> alkylamino, hydroxy-C<sub>2-4</sub> alkylamino, C<sub>2-4</sub> alkanoyloxy-C<sub>2-4</sub> alkylamino, C<sub>1-4</sub> alkoxy-C<sub>2-4</sub> alkylamino, carboxy-C<sub>1-4</sub> alkylamino, C<sub>1-4</sub> alkoxycarbonyl-C<sub>1-4</sub> alkylamino, carbamoyl-C<sub>1-4</sub> alkylamino, N-C<sub>1-4</sub> alkylcarbamoyl-C<sub>1-4</sub> alkylamino, N,N-di-[C<sub>1-4</sub> alkyl]carbamoyl-C<sub>1-4</sub> alkylamino, amino-C<sub>2-4</sub> alkylamino, C<sub>1-4</sub> alkylamino-C<sub>2-4</sub> alkylamino, di-[C<sub>1-4</sub>alkyl]amino-C<sub>2-4</sub> alkylamino, phenyl-C<sub>1-4</sub> alkylamino, phenoxy-C<sub>2-4</sub> alkylamino, anilino-C<sub>2-4</sub> alkylamino, 4-pyridon-1-yl- C<sub>2-4</sub> alkylamino, pyrrolidin-1-yl-C<sub>2-4</sub> alkylamino, imidazol-1-yl-C<sub>2-4</sub> alkylamino, piperidino-C<sub>2-4</sub> alkylamino, morpholino-C<sub>2-4</sub> alkylamino, thiomorpholino-C<sub>2-4</sub> alkylamino, thiomorpholino-1-oxide-C<sub>2-4</sub> alkylamino, thiomorpholino-1,1-dioxide-C<sub>2-4</sub> alkylamino, piperazin-1-yl-C<sub>2-4</sub>alkylamino, 4-(C<sub>1-4</sub>alkyl)piperazin-1-yl-C<sub>2-4</sub>alkylamino, phenylthio-C<sub>2-4</sub> alkylamino, C<sub>2-4</sub> alkanoylamino, C<sub>1-4</sub> alkoxycarbonylamino, C<sub>1-4</sub> alkylsulphonylamino, C<sub>1-4</sub> alkylsulphinylamino, benzamido, benzenesulphonamido, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, halogeno-C<sub>2-4</sub> alkanoylamino, hydroxy-C<sub>2-4</sub> alkanoylamino, hydroxy-C<sub>2-4</sub> alkanoyl-(C<sub>1-4</sub> alkyl)-amino, C<sub>1-4</sub> alkoxy-C<sub>2-4</sub> alkanoylamino,

Atty. Docket No.: PG3119US2

carboxy-C<sub>2-4</sub> alkanoylamino, C<sub>1-4</sub> alkoxycarbonyl-C<sub>2-4</sub> alkanoylamino, carbamoyl-C<sub>2-4</sub> alkanoylamino, N-C<sub>1-4</sub> alkylcarbamoyl-C<sub>2-4</sub> alkanoylamino, N,N-di-[C<sub>1-4</sub> alkyl]carbamoyl-C<sub>2-4</sub> alkanoylamino, amino-C<sub>2-4</sub> alkanoylamino, C<sub>1-4</sub> alkylamino-C<sub>2-4</sub> alkanoylamino and ~~or~~ di-[C<sub>1-4</sub> alkyl]amino-C<sub>2-4</sub> alkanoylamino; and wherein said benzamido or benzenesulphonamido substituent or any anilino, phenoxy or phenyl group on a R<sup>3</sup> substituent ~~may~~ optionally has have one or two halogeno, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy substituents; and wherein any substituent having a heterocyclic ring may optionally has have one or two halogeno, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy substituents on said ring; and wherein any substituent having a heterocyclic ring ~~may~~ optionally has have one or two oxo or thioxo substituents on said ring;

or R<sup>3</sup> is selected from the group consisting of ~~represents a group selected from~~ M<sup>1</sup>-M<sup>2</sup>-M<sup>3</sup>-M<sup>4</sup>, M<sup>1</sup>-M<sup>5</sup> and ~~or~~ M<sup>1</sup>-M<sup>2</sup>-M<sup>3</sup>'-M<sup>6</sup>

wherein

M<sup>1</sup> is ~~represents~~ a C<sub>1-4</sub> alkyl group, wherein optionally a CH<sub>2</sub> group is replaced by a CO group;

M<sup>2</sup> is ~~represents~~ NR<sup>12</sup> or CR<sup>12</sup>R<sup>13</sup>, in which R<sup>12</sup> and R<sup>13</sup> each independently are ~~represent~~ H or C<sub>1-4</sub> alkyl;

M<sup>3</sup> is ~~represents~~ a C<sub>1-4</sub> alkyl group;

M<sup>3'</sup> is ~~represents~~ a C<sub>1-4</sub> alkyl group or is absent;


M<sup>4</sup> is selected from the group consisting of ~~represents~~ CN, NR<sup>12</sup>S(O)<sub>m</sub>R<sup>13</sup>, S(O)<sub>m</sub>NR<sup>14</sup>R<sup>15</sup>, CONR<sup>14</sup>R<sup>15</sup>, S(O)<sub>m</sub>R<sup>13</sup> and ~~or~~ CO<sub>2</sub>R<sup>13</sup>, in which R<sup>12</sup>, R<sup>13</sup> and m are as defined above and R<sup>14</sup> and R<sup>15</sup> each independently are ~~represent~~ H or C<sub>1-4</sub> alkyl, or R<sup>14</sup> and R<sup>15</sup> together with the nitrogen atom to which they are attached form a 5-or 6-membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O or S(O)<sub>m</sub> in which ring any nitrogen atom present is ~~may~~

Atty. Docket No.: PG3119US2

optionally ~~be~~ substituted with a C<sub>1-4</sub> alkyl group, and which ring may optionally ~~has~~ have one or two oxo or thioxo substituents;

M<sup>5</sup> ~~is represents~~ the group NR<sup>14</sup>R<sup>15</sup>, wherein R<sup>14</sup> and R<sup>15</sup> are as defined above, or

M<sup>5</sup> ~~is represents~~ the group



in which t ~~is represents~~ 2 to 4 and R<sup>16</sup> ~~is represents~~ OH, OC<sub>1-4</sub> alkyl or NR<sup>14</sup>R<sup>15</sup>; and

M<sup>6</sup> ~~is selected from the group consisting of~~ represents a C<sub>3-6</sub> cycloalkyl group, the group NR<sup>14</sup>R<sup>15</sup>, wherein R<sup>14</sup> and R<sup>15</sup> are as defined above, and or a 5- or 6-membered heterocyclic ring system containing 1 to 4 heteroatoms selected from N, O or S;

and p is 0 to 3; or when p is 2 or 3, two adjacent R<sup>3</sup> groups together form an optionally substituted methylenedioxy or ethylenedioxy group;

R<sup>2</sup> is selected from the group consisting of hydrogen, halogen, trifluoromethyl, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> alkoxy;

U ~~is represents~~ phenyl or a 5 to 10-membered mono or bicyclic ring system in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S(O)<sub>m</sub>, wherein m is 0, 1 or 2, and wherein U is substituted by at least one independently selected R<sup>6</sup> group and U is optionally substituted by at least one independently selected R<sup>4</sup> group;

Atty. Docket No.: PG3119US2

each  $R^4$  is independently selected from the group consisting of hydrogen, hydroxy, halogen,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylamino, di- $[C_{1-4}$  alkyl]amino,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylsulphinyl,  $C_{1-4}$  alkylsulphonyl,  $C_{1-4}$  alkylcarbonyl,  $C_{1-4}$  alkylcarbamoyl, di- $[C_{1-4}$  alkyl] carbamoyl, carbamyl,  $C_{1-4}$  alkoxy carbonyl, cyano, nitro and ~~or~~ trifluoromethyl;

each  $R^6$  is independently a group  $ZR^7$  wherein Z is joined to  $R^7$  through a  $(CH_2)_p$  group in which p is 0, 1 or 2 and Z is selected from a group consisting of ~~represents a group~~  $V(CH_2)$ ,  $V(CF_2)$ ,  $(CH_2)V$ ,  $(CF_2)V$ ,  $V(CRR')$ ,  $V(CHR)$  and ~~or~~ V where R and R' are each  $C_{1-4}$  alkyl and in which V is a hydrocarbonyl group containing 0, 1 or 2 carbon atoms, carbonyl, dicarbonyl,  $CH(OH)$ ,  $CH(CN)$ , sulphonamide, amide, O,  $S(O)_m$  or  $NR^b$  where  $R^b$  is hydrogen or  $R^b$  is  $C_{1-4}$  alkyl; and  $R^7$  is an optionally substituted  $C_{3-6}$  cycloalkyl; or an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety; or  $R^6$  is a group  $ZR^7$  in which Z is  $NR^b$ , and  $NR^b$  and  $R^7$  together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety.

Claim 2 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible breast cancer.

Claim 3 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible non-small cell lung cancer.

Claim 4 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible ovarian cancer.

Atty. Docket No.: PG3119US2

Claim 5 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible stomach cancer.

Claim 6 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible pancreatic cancer.

Claim 7 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible head and neck cancer.

Claim 8 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible cancer in which there is ~~characterized by~~ expression or over-expression of EGFR.

Claim 9 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible cancer in which there is ~~characterized by~~ expression or over-expression of erbB-2.

Claim 10 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible cancer in which there is ~~characterized by~~ expression or over-expression of EGFR and erbB-2.

Claim 11 (Currently Amended): The A method as claimed in claim 1, wherein X is N.


Claim 12 (Currently Amended): The A method as claimed in claim 1, wherein Y is  $\text{NR}^b$ ,  $\text{NR}^b(\text{CH}_2)$ , or  $(\text{CH}_2)\text{NR}^b$ , ~~preferably Y is  $\text{NR}^b$  and  $\text{R}^b$  is preferably hydrogen or methyl.~~

Claim 13 (Currently Amended): The A method as claimed in claim 1, wherein  $\text{R}^1$  is a 5- or 6-membered heterocyclic ring as defined in claim 1 substituted with

Atty. Docket No.: PG3119US2

an  $R^3$  group selected from the group consisting of  $M^1$ - $M^2$ - $M^3$ - $M^4$ ,  $M^1$ - $M^5$  and or  $M^1$ - $M^2$ - $M^3$ - $M^6$  as defined in claim 1 ~~or claim 2~~; and  $p = 0$ .

Claim 14 (Currently Amended): The A method as claimed in claim 1, wherein  $M^1$  ~~is~~ represents  $CH_2$ ,  $CO$ ,  $CH_2CH_2$  or  $CH_2CO$ ;  $M^2$  ~~is~~ represents  $NR^{12}$  in which  $R^{12}$  is as defined in claim 1;  $M^3$  ~~is~~ represents  $CH_2$ ,  $CH_2CH_2$  or propyl;  $M^3$  ~~is~~ represents  $CH_2$ , ethyl, propyl, isopropyl or is absent;  $M^4$  ~~is~~ represents  $SOR^{13}$ ,  $SO_2R^{13}$ ,  $NR^{12}SO_2R^{13}$ ,  $SO_2NR^{14}R^{15}$ ,  $CO_2R^{13}$  or  $CONR^{14}R^{15}$  in which  $R^{12}$  and  $R^{13}$  are defined in claim 1 and  $R^{14}$  and  $R^{15}$  each independently are represent H or  $C_{1-4}$  alkyl;  $M^5$  ~~is~~ represents a group  $NR^{14}R^{15}$  in which  $R^{14}$  and  $R^{15}$  together with the nitrogen atom to which they are attached ~~is~~ represent a 6-membered ring optionally containing an additional heteroatom selected from N or O, in which ring any nitrogen atom present ~~is~~ may optionally be substituted with a  $C_{1-4}$  alkyl group; or  $M^5$  ~~is~~ represents a group



in which  $t$  ~~is~~ represents 2 or 3 and  $R^{16}$  ~~is~~ represents OH,  $NH_2$ ,  $N(C_{1-4} \text{ alkyl})_2$  or  $OC_{1-4} \text{ alkyl}$ ; ~~more preferably~~  $R^{16}$  ~~represents~~  $NH_2$  or  $N(CH_3)_2$ ; or  $M^5$  ~~is~~ represents a group  $NR^{14}R^{15}$  in which  $R^{14}$  and  $R^{15}$  each independently are represent hydrogen or  $C_{1-4}$  alkyl, ~~more preferably~~ hydrogen, methyl, ethyl or isopropyl; and  $M^6$  ~~is~~ represents a group  $NR^{14}R^{15}$  in which  $R^{14}$  and  $R^{15}$  each independently ~~is~~ represents  $C_{1-4}$  alkyl, ~~more preferably~~ methyl; or  $R^{14}$  and  $R^{15}$  together with the nitrogen atom to which they are attached ~~is~~ represent a 5- or 6-membered ring optionally containing an additional heteroatom selected from N or O, in which ring any nitrogen atom present ~~is~~ may optionally be substituted with a  $C_{1-4}$  alkyl group, ~~preferably a methyl group~~; or  $M^6$  ~~is~~ represents a 5- or 6-membered heterocyclic ring system containing 1 or 2 heteroatoms selected from N or O.

Claim 15 (Currently Amended): The A method as claimed in claim 1, wherein  $M^2$ - $M^3$ - $M^4$  ~~is~~ represents a methylsulphonylethylamino, methylsulphinylethylamino, methylsulphonylethyl(methylamino), methylsulphinylethyl(methylamino), methylsulphonylpropylamino, methylsulphinylpropylamino,



Atty. Docket No.: PG3119US2

methylsulphonamidoethylamino, aminosulphonylethylamino, methylaminosulphonylethylamino, sarcosinamide, glycine, glycinamide, glycine methyl ester or acetylaminoethylamino group.

Claim 16 (Currently Amended): The A method as claimed in claim 1, wherein  $R^1$  is selected from the group consisting of comprising furan, dihydrofuran, thiophene, imidazole, tetrazole, triazole, pyridine, pyrrole, pyrimidine, isoxazole and or oxadiazole.

Claim 17 (Currently Amended): The A method as claimed in claim 1, wherein  $R^1$  is selected from the group consisting of comprising furan, imidazole, oxadiazole (~~particularly 1,3,4-oxadiazole and 1,2,4-oxadiazole~~) and triazole (~~particularly 1,2,3-triazole and 1,3,4-triazole~~).

Claim 18 (Currently Amended): The A method as claimed in claim 1, wherein  $R^6$  is benzyl, fluorobenzyl, difluorobenzyl, benzyloxy, fluorobenzyloxy, pyridylmethyl, phenyl, benzenesulphonyl, phenoxy or fluorophenoxy.

Claim 19 (Currently Amended): The A method as claimed in claim 1, wherein U is represents an phenyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group.

Claim 20 (Currently Amended): The A method as claimed in claim 1, wherein U is represents a phenyl or 1H-indazolyl group.

Claim 21 (Currently Amended): The A method as claimed in claim 1, wherein the optional substituents for the carbocyclic or heterocyclic moiety ~~and also for other optionally substituted groups~~ include hydroxy, halogen, trifluoromethyl, trifluoromethoxy, nitro, amino, cyano, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkyl carbonyl, carboxylate and C<sub>1-4</sub> alkoxy carboxyl.

Claim 22 (Currently Amended): The A method as claimed in claim 1, wherein X is represents N; Y is represents NR<sup>a</sup>, wherein R<sup>a</sup> is hydrogen or C<sub>1-4</sub> alkyl; R<sup>1</sup> is

Atty. Docket No.: PG3119US2

represents furan, thiophene, pyrrole, pyridine, pyrimidine, pyrazine, imidazole, oxazole, isoxazole, oxadiazole, tetrazole, triazole, dioxolane or a partially or fully hydrogenated derivative of any of these groups, optionally substituted by one or more  $R^3$  groups selected from halo, trifluoromethyl,  $C_{1-4}$  alkyl, carboxy,  $C_{1-4}$  alkoxy, carbonyl, formyl, hydroxy- $C_{1-4}$  alkyl, 1,3-dioxolan-2-yl, amino,  $C_{1-4}$  alkylamino, di( $C_{1-4}$  alkyl)amino, hydroxy- $C_{1-4}$ alkanoyl-( $C_{1-4}$ alkyl)-amino,  $C_{1-4}$  alkylamino- $C_{1-4}$  alkyl or di( $C_{1-4}$  alkyl)amino- $C_{1-4}$  alkyl; p is 0;  $R^2$  is represents hydrogen;  $R^4$  is represents hydrogen, halo or methyl; U is represents phenyl, indolyl, benzimidazolyl or indazolyl, more preferably phenyl or indazolyl; and  $R^6$  is represents phenyl, benzyl,  $\alpha$ -methylbenzyl, fluorobenzyl, difluorobenzyl, pyridylmethyl, benzenesulphonyl, phenoxy, fluorophenoxy, benzyloxy or fluorobenzyloxy.

Claim 23 (Currently Amended): The A method as claimed in claim 1, wherein X is represents N; Y is represents  $NR^a$ , wherein  $R^a$  is hydrogen or  $C_{1-4}$  alkyl;  $R^1$  is selected from the group consisting of represents a furan, dihydrofuran, thiophene, pyridine, pyrrole, pyrimidine, isoxazole, triazole, tetrazole, imidazole and or oxadiazole ring, preferably furan, imidazole, oxadiazole and triazole, substituted with an  $R^3$  group selected from the group consisting of  $C_{1-4}$ alkyl,  $C_{1-4}$ alkylamino- $C_{1-4}$ alkyl, di( $C_{1-4}$ alkyl)amino- $C_{1-4}$  alkyl, formyl, carboxy,  $C_{1-4}$ alkoxy, carbonyl, dioxolanyl, trifluoromethyl, methylsulphonylethylaminomethyl, methylsulphonylethylamino-carbonyl, methylsulphonylethyl(methylamino)-methyl, methylsulphonamidoethylamino-methyl, aminosulphonylethylamino-methyl, methylaminosulphonylethylamino-methyl, N,N-dimethylaminoprop-2-ylaminomethyl, N-(2-dimethylaminoethyl)-N-ethylaminomethyl, pyridylaminomethyl, tetrahydrofuranomethylaminomethyl, piperazinylmethyl, methylpiperazinylmethyl, piperidinylmethyl, pyridylmethyl, N-(prolinamido)methyl and or (N,N-dimethyl-prolinamido)methyl; p is 0;  $R^2$  is represents hydrogen;  $R^4$  is represents hydrogen or halo; U is represents phenyl or indazolyl; and  $R^6$  is selected from the group consisting of represents benzyl, fluorobenzyl, difluorobenzyl, pyridylmethyl, benzenesulphonyl, phenoxy, benzyloxy or fluorobenzyloxy.